HopeStage
Back to all studies
CompletedNCT01093937

Study of Varenicline (Champix) for Smoking Cessation/Reduction in Patients With Bipolarity

Medication studyAges 18–65Canada
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
TorontoSee all locations and recruitment

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateNovember 2009
Recruitment status
Completed
Enrollment listed in the registry
30
Sponsor
Centre for Addiction and Mental Health
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Drug
Locations
Canada
Age range
From 18 Years to 65 Years
Official registry ID
NCT01093937
Official title
Show the full official title

A 10-Week Pilot Study of Varenicline (Champix) Versus Placebo for Smoking Cessation/Reduction in Patients With Bipolar Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Toronto

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Centre for Addiction and Mental Health, a hospital or academic medical center.

Did this study involve medication?

Yes. The study involved medication, including varenicline.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies